| Medibank Private Limited (MPL) ORDINARY FULLY PAID |
Financials |
$12,310 |
HY25 Results - Investor Presentation
|
27 Feb 2025 8:08AM |
$4.020 |
$4.470 |
risen by
11.19%
|
|
MPL - Price-sensitive ASX Announcement
Full Release
Key Points
- Underlying NPAT increased by 13.8% to $298.7 million.
- Interim fully franked dividend of 7.8 cents per share, up 8.3%.
- COVID-19 financial support package of $160 million announced.
- Medibank Health segment profit rose 40.8% to $37.6 million.
- Strong focus on disciplined growth in both resident and non-resident health insurance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Austco Healthcare Limited (AHC) ORDINARY FULLY PAID |
Health Care |
$146 |
Austco Healthcare HY Dec 24 Results Media Release
|
27 Feb 2025 8:08AM |
$0.300 |
$0.390 |
risen by
30%
|
|
AHC - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from customers increased by 62% to $36.9 million.
- EBITDA rose by 150% from $2.1 million to $5.2 million.
- Net Profit Before Tax increased by 270% from $1.0 million to $3.9 million.
- Unfilled Contracted Revenue steady at $50.2 million.
- Growth driven by acquisitions and strong organic growth in Asia and North America.
- Company focuses on innovation, product development, and sustainable growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Austco Healthcare Limited (AHC) ORDINARY FULLY PAID |
Health Care |
$146 |
Austco Healthcare Appendix 4D and HY Dec 24 Results
|
27 Feb 2025 8:08AM |
$0.300 |
$0.390 |
risen by
30%
|
|
AHC - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue increased by 61.6% to $36.9 million.
- Net profit after tax rose by 150.1% to $2.9 million.
- Successful integration of acquired businesses contributed $11.9 million in revenue.
- Unfilled Contracted Revenue stands at $50.2 million.
- Cash position improved to $14.9 million, debt-free status maintained.
- Research and Development investment remained steady at $2.3 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Medibank Private Limited (MPL) ORDINARY FULLY PAID |
Financials |
$12,310 |
HY25 Results - Media Release
|
27 Feb 2025 8:08AM |
$4.020 |
$4.470 |
risen by
11.19%
|
|
MPL - Price-sensitive ASX Announcement
Full Release
Key Points
- Operating profit up 10.2% to $349.2 million.
- Medibank Health segment profit increased by 40.8%.
- Underlying net profit after tax rose by 13.8% to $298.7 million.
- Dividend increased to 7.8 cents per share, up 8.3% from the previous year.
- Non-resident policy unit growth of 12.6% driven largely by students.
- Total claims paid reached $3.3 billion.
- $160 million cash give back announced as part of COVID-19 support.
- Customer growth in the resident segment showed an increase of 18,500 policyholders.
- Company continues to invest in health transition and customer care initiatives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Silk Logistics Holdings Limited (SLH) ORDINARY FULLY PAID |
Industrials |
- |
Scheme Update
|
27 Feb 2025 8:08AM |
$2.070 |
$2.140 |
risen by
3.38%
|
|
| McMillan Shakespeare Limited (MMS) ORDINARY FULLY PAID |
Industrials |
$1,222 |
Appendix 4D and Half Year Report
|
27 Feb 2025 8:07AM |
$14.060 |
$17.540 |
risen by
24.75%
|
|
MMS - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from continuing operations rose by 7.9% to $276,829,000.
- Net profit after tax attributable to members was $45,224,000.
- Interim dividend declared at 71 cents per share.
- No significant changes in the nature of activities during the period.
- The Simply Stronger program aims to enhance digital experiences and operational efficiencies.
- Normalised UNPATA from continuing operations was $49,634,000.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Medibank Private Limited (MPL) ORDINARY FULLY PAID |
Financials |
$12,310 |
Dividend/Distribution - MPL
|
27 Feb 2025 8:07AM |
$4.020 |
$4.470 |
risen by
11.19%
|
|
| GTN Limited (GTN) ORDINARY FULLY PAID |
Communication Services |
$51 |
Update - Notification of buy-back - GTN
|
27 Feb 2025 8:07AM |
$0.535 |
$0.265 |
fallen by
50.47%
|
|
| MAAS Group Holdings Limited (MGH) ORDINARY FULLY PAID |
Industrials |
$1,523 |
Update - Notification of buy-back - MGH
|
27 Feb 2025 8:07AM |
$3.850 |
$4.220 |
risen by
9.61%
|
|
| Vitura Health Limited (VIT) ORDINARY FULLY PAID |
Health Care |
$33 |
Change of Director's Interest Notice
|
27 Feb 2025 8:07AM |
$0.087 |
$0.050 |
fallen by
42.53%
|
|
| Medibank Private Limited (MPL) ORDINARY FULLY PAID |
Financials |
$12,310 |
HY25 Results - Appendix 4D and Financial Report
|
27 Feb 2025 8:07AM |
$4.020 |
$4.470 |
risen by
11.19%
|
|
MPL - Price-sensitive ASX Announcement
Full Release
Key Points
- Group operating profit increased by 12.7% to $360.1 million.
- Health insurance revenue rose by 5.0% to $4,113.9 million.
- Net profit after tax attributable to shareholders decreased by 0.8% to $340.3 million.
- Interim dividend declared at 7.8 cents per share.
- Strong performance in the Medibank Health segment with a 40.8% profit increase.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Imricor Medical Systems Inc (IMR) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$696 |
FY24 Results Investor Presentation
|
27 Feb 2025 8:07AM |
$1.460 |
$2.170 |
risen by
48.63%
|
|
IMR - Price-sensitive ASX Announcement
Full Release
Key Points
- Imricor's technology enables cardiac procedures without ionizing radiation.
- Revenue of US $959k in FY2024, up 56% from the previous year.
- The company is the only one globally with MRI-compatible devices for cardiac procedures.
- Imricor's products are approved in 31 countries, with growth expected in several markets.
- The NorthStar 3D Mapping System is critical for the future of iCMR labs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| L1 Long Short Fund Limited (LSF) ORDINARY FULLY PAID |
Financials |
$2,703 |
Net Tangible Asset Backing
|
27 Feb 2025 8:07AM |
$2.740 |
$4.270 |
risen by
55.84%
|
|
| IDP Education Limited (IEL) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,383 |
Dividend/Distribution - IEL
|
27 Feb 2025 8:07AM |
$11.790 |
$4.970 |
fallen by
57.85%
|
|
| Medibank Private Limited (MPL) ORDINARY FULLY PAID |
Financials |
$12,310 |
Medibank to return $160m to customers
|
27 Feb 2025 8:07AM |
$4.020 |
$4.470 |
risen by
11.19%
|
|
| IDP Education Limited (IEL) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,383 |
H1 FY25 Investor Presentation
|
27 Feb 2025 8:07AM |
$11.790 |
$4.970 |
fallen by
57.85%
|
|
IEL - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue of A$475.4 million down 16%
- Adjusted EBIT of A$92.7 million down 40%
- Student Placement volumes down 15%
- English Language Testing volumes down 19%
- Overhead costs reduced by 14%
- GOCF conversion rate improved to 64%
- Average price growth of 14% in Student Placement
- Maintained student NPS above 70, reflecting positive student experience
- Strong focus on technology and innovation for efficiency and user experience
- Positioned to expand market share despite challenging conditions
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Imricor Medical Systems Inc (IMR) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$696 |
Imricor Releases FY24 Results
|
27 Feb 2025 8:07AM |
$1.460 |
$2.170 |
risen by
48.63%
|
|
IMR - Price-sensitive ASX Announcement
Full Release
Key Points
- First module submitted and returned by US FDA with no deficiencies
- NorthStar submitted for CE Mark approval in Europe
- First MRI guided ablation on US soil performed at Johns Hopkins as part of VISABL-AFL
- Saudi FDA approval received, registration completed in Qatar opening Middle East
- CE Mark approval of MR Vision diagnostic catheter
- VISABL-AFL global pivotal trial commences enrolment in France, US and Switzerland
- Global rollout underway with new site activations in France, Netherlands, Croatia and Switzerland
- Installation complete in Hungary, first procedures being scheduled
- First purchase orders received from Qatar initiating expansion into Middle East
- Group revenue of US$959k + 56% on prior year
- Operating costs well contained down 1% to $17.3m including R&D investment
- Strong balance sheet US$15.7m cash in place to fund major milestones in 2025
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| IDP Education Limited (IEL) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,383 |
H1 FY25 Results Announcement
|
27 Feb 2025 8:07AM |
$11.790 |
$4.970 |
fallen by
57.85%
|
|
IEL - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue of $475.4 million, down 16%
- Adjusted EBIT of $92.7 million, down 40%
- Overhead costs down 14% to $167.8 million
- Student Placement volumes decreased by 27%
- English Language Testing volumes down 24%
- Interim dividend of 9.0 cents per share declared
- Cost discipline and market share growth emphasized
- Long-term growth drivers for international education remain positive
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Change Financial Limited (CCA) ORDINARY FULLY PAID |
Financials |
$57 |
H1 FY25 Investor Presentation
|
27 Feb 2025 8:07AM |
$0.067 |
$0.083 |
risen by
23.88%
|
|
| Change Financial Limited (CCA) ORDINARY FULLY PAID |
Financials |
$57 |
H1 FY25 Results Summary
|
27 Feb 2025 8:07AM |
$0.067 |
$0.083 |
risen by
23.88%
|
|
| IDP Education Limited (IEL) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,383 |
H1 FY 25 Interim Financial Report
|
27 Feb 2025 8:07AM |
$11.790 |
$4.970 |
fallen by
57.85%
|
|
IEL - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue for H1 FY25 decreased by 18% to $475.4 million.
- Net profit after tax fell by 39% to $59.7 million.
- Student placement revenue dropped by 15% to $244.2 million.
- English language testing revenue declined by 22%.
- Revenue decline was attributed to decreased student volumes in major markets.
- Australasia segment recorded a 27% revenue increase.
- Net debt increased to $191 million.
- Cash and cash equivalents at the end of the half-year were $156.9 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Solvar Limited (SVR) ORDINARY FULLY PAID |
Financials |
$344 |
Update - Notification of buy-back - SVR
|
27 Feb 2025 8:06AM |
$1.440 |
$1.820 |
risen by
26.39%
|
|
| Change Financial Limited (CCA) ORDINARY FULLY PAID |
Financials |
$57 |
Half Yearly Report and Accounts
|
27 Feb 2025 8:06AM |
$0.067 |
$0.083 |
risen by
23.88%
|
|
CCA - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 61% to US$7,193,111 for the half year ended 31 December 2024.
- Operating loss for the period was US$1,731,201, an increase of 13% from last year.
- The company aims for over 30% revenue growth and a positive EBITDA in FY25.
- Exit from the US market expected to significantly reduce operating expenses.
- Focus on solidifying client base and building new partnerships.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Imricor Medical Systems Inc (IMR) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$696 |
Appendix 4E and FY24 Financial Accounts
|
27 Feb 2025 8:06AM |
$1.460 |
$2.170 |
risen by
48.63%
|
|
IMR - Price-sensitive ASX Announcement
Full Release
Key Points
- Imricor Medical Systems Inc focuses on MRI-guided technology for cardiac procedures.
- Total revenues increased to $959,424 in 2024 from $615,568 in 2023.
- The company reported a net loss of approximately $29.69 million for 2024.
- There are concerns regarding the company's ability to continue as a going concern.
- The company has faced recurring operational losses and negative cash flows.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Brambles Limited (BXB) ORDINARY FULLY PAID |
Industrials |
$32,891 |
Update - Notification of buy-back - BXB
|
27 Feb 2025 8:06AM |
$20.980 |
$24.220 |
risen by
15.44%
|
|
Call 1300 880 160
Start a chat
Schedule a call
